A mid-size pharmaceutical company that unexpectedly obtained a marketed therapy in an adjacent therapeutic area as one of their existing therapies was in need of knowing what financial impact the sudden addition would have on the organization. Given the complexity of the market and potential synergies between the two drugs, it was requested that Kineticos provide a prescription-based forecast model for the newly re-acquired therapy, taking into account factors such as sales force sizing, advertising & promotional spend, pricing, and managed care acceptance.
NOTE: Use your cursor or the tool-bar located at the bottom to review all available pages, including example deliverables.
To download the full case study including example deliverables, click here: Indication Prioritization and Forecasting
Subscribe to the Kineticos Research Institute to receive weekly emails containing insightful content.